NovoCure Limited NVCR NASDAQ

NovoCure Limited (NVCR) reported total assets of $804.33M and total liabilities of $463.86M for fiscal year 2025, resulting in total equity of $340.47M.

The company held $457.52M in cash and short-term investments. Total debt stood at $290M, with net debt of $186.61M. The Debt-to-Equity (D/E) ratio was 0.85 (moderate).

Current ratio is 2.9, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (75/100, Pass) — Debt-to-Equity of 0.85, current ratio of 2.9 — balance sheet is strong
• MOAT (61/100) — Total assets $804.33M and equity $340.47M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.85 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 51/100 with 3/7 criteria passed.

PODD

Insulet Corporation

$201.49

+1.86%

PEN

Penumbra, Inc.

$332.17

+0.21%

GMED

Globus Medical, Inc.

$94.94

+2.11%

SWAV

ShockWave Medical, Inc.

$334.75

-0.02%

MASI

Masimo Corporation

$178.39

-0.04%

NARI

Inari Medical, Inc.

$79.97

+0.00%

IRTC

iRhythm Technologies, Inc.

$123.23

+2.31%

TMDX

TransMedics Group, Inc.

$115.68

+2.05%